Navitor Pharmaceuticals
Cambridge
About Navitor Pharmaceuticals
Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $98.2M
- Last round: Series Unknown (Apr 2020)
- Website: navitorpharma.com
- Phone: 781-538-6113
Industries & Categories
Biopharma, Biotechnology, Developer Platform, Health Diagnostics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/navitor-pharmaceuticals-134509 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.